Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 2/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.50 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CHKA | P35790 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738784 | 0.95 | HRH3 (0.67) | HRH3HRH4ALDH1A1KDM4ENCF1 | |
| SCHEMBL447560 | 0.93 | HRH3 (0.71) | HRH3HRH4ALDH1A1KDM4ENCF1 | |
| SCHEMBL996532 | 0.93 | HRH3 (0.71) | HRH3HRH4ALDH1A1KDM4ENCF1 | |
| SCHEMBL28282914 | 0.91 | HRH3 (0.68) | HRH3HRH4ALDH1A1KDM4ENCF1 | |
| SCHEMBL27745775 | 0.88 | HRH3 (0.57) | HRH3HRH4ALDH1A1KDM4ENCF1 | |
| SCHEMBL18227661 | 0.87 | CHKA (0.70) | HRH3ALDH1A1KDM4ENCF1CHKA | |
| SCHEMBL742562 | 0.81 | MC4R (0.66) | HRH3ALDH1A1KDM4ENCF1CHKA | |
| SCHEMBL2475809 | 0.81 | ALDH1A1 (0.63) | HRH3ALDH1A1KDM4ENCF1SIGMAR1 | |
| SCHEMBL759019 | 0.81 | SIGMAR1 (0.66) | HRH3ALDH1A1CXCR4CYP2C19SIGMAR1 | |
| SCHEMBL2971636 | 0.81 | KDM4E (0.61) | HRH3ALDH1A1KDM4EL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114787160-A | Imidazopyridazines and imidazopyridines as activin receptor-like kinase-2 inhibitors | 因赛特公司 | 2022-07-22 | — | — | CN | claimed |
| EP-3898627-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE-2 | Incyte Corporation (US) | 2021-10-27 | — | — | EP | claimed |
| WO-2020132197-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE-2 | INCYTE CORPORATION (US) | 2020-06-25 | — | — | WO | claimed |
| US-20200199131-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-25 | — | — | US | claimed |
| US-12030889-B2 | Imidazopyridazine and imidazopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| CN-114787160-A | Imidazopyridazines and imidazopyridines as activin receptor-like kinase-2 inhibitors | 因赛特公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3898627-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE-2 | Incyte Corporation (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020132197-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE-2 | INCYTE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200199131-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| EP-0993448-A1 | (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 2000-04-19 | — | — | EP | disclosed |
| EP-0991638-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998057934-A1 | (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998057951-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030889-B2 | Imidazopyridazine and imidazopyridine compounds and uses thereof | ALK, ABL2, ACVR2A | HRH3 1130/4885HRH4 564/4885ALDH1A1 25/4885 |
| US-20200199131-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | ALK, ABL2, ACVR2A | HRH3 1130/4885HRH4 564/4885ALDH1A1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.